Lexaria Bioscience Corp Stock Earnings Per Share

LEXXW Stock

USD 0.55 0.05 8.33%

Lexaria Bioscience Corp fundamentals help investors to digest information that contributes to Lexaria Bioscience's financial success or failures. It also enables traders to predict the movement of Lexaria Stock. The fundamental analysis module provides a way to measure Lexaria Bioscience's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lexaria Bioscience stock.

Other Current Liab Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Lexaria Bioscience Corp Company Earnings Per Share Analysis

Lexaria Bioscience's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.

Earnings per Share

Earnings

Average Shares

More About Earnings Per Share | All Equity Analysis

Lexaria Earnings Per Share Driver Correlations

Understanding the fundamental principles of building solid financial models for Lexaria Bioscience is extremely important. It helps to project a fair market value of Lexaria Stock properly, considering its historical fundamentals such as Earnings Per Share. Since Lexaria Bioscience's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lexaria Bioscience's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lexaria Bioscience's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Current Deferred Revenue	Net Receivables	Short Term Debt	Intangible Assets	Long Term Debt	Capital Surpluse	Property Plant Equipment	Net Invested Capital	Net Working Capital	Short Term Investments	Capital Stock	Short Long Term Debt
Total Assets		0.99	-0.89	-0.71	0.64	0.28	0.96	-0.58	-0.45	0.44	-0.23	0.78	-0.6	0.66	0.72	0.72	0.56	0.66	-0.83	-0.52
Total Stockholder Equity	0.99		-0.94	-0.73	0.59	0.15	0.99	-0.55	-0.51	0.43	-0.31	0.79	-0.64	0.7	0.73	0.77	0.61	0.72	-0.85	-0.49
Net Debt	-0.89	-0.94		0.7	-0.46	0.12	-0.97	0.41	0.52	-0.35	0.43	-0.72	0.67	-0.7	-0.68	-0.79	-0.67	-0.77	0.79	0.33
Retained Earnings	-0.71	-0.73	0.7		-0.69	-0.09	-0.75	0.34	0.44	-0.38	0.6	-0.97	0.82	-0.9	-0.9	-0.3	-0.11	-0.32	0.85	0.45
Accounts Payable	0.64	0.59	-0.46	-0.69		0.42	0.62	-0.45	0.11	0.0	-0.24	0.74	-0.43	0.45	0.57	0.0	-0.22	-0.1	-0.64	-0.79
Total Liab	0.28	0.15	0.12	-0.09	0.42		0.05	-0.43	0.16	0.17	0.4	0.12	0.15	-0.02	0.05	-0.15	-0.19	-0.18	-0.15	-0.15
Total Current Assets	0.96	0.99	-0.97	-0.75	0.62	0.05		-0.49	-0.46	0.38	-0.39	0.8	-0.67	0.7	0.73	0.74	0.58	0.68	-0.85	-0.52
Common Stock	-0.58	-0.55	0.41	0.34	-0.45	-0.43	-0.49		0.55	0.14	-0.28	-0.42	-0.07	-0.14	-0.27	-0.45	-0.36	-0.38	0.73	0.3
Current Deferred Revenue	-0.45	-0.51	0.52	0.44	0.11	0.16	-0.46	0.55		-0.25	0.18	-0.43	0.3	-0.45	-0.43	-0.72	-0.7	-0.77	0.68	-0.12
Net Receivables	0.44	0.43	-0.35	-0.38	0.0	0.17	0.38	0.14	-0.25		-0.2	0.39	-0.52	0.6	0.52	0.38	0.35	0.47	-0.21	-0.01
Short Term Debt	-0.23	-0.31	0.43	0.6	-0.24	0.4	-0.39	-0.28	0.18	-0.2		-0.47	0.6	-0.53	-0.47	-0.17	-0.08	-0.2	0.34	0.18
Intangible Assets	0.78	0.79	-0.72	-0.97	0.74	0.12	0.8	-0.42	-0.43	0.39	-0.47		-0.79	0.88	0.94	0.36	0.14	0.34	-0.87	-0.59
Long Term Debt	-0.6	-0.64	0.67	0.82	-0.43	0.15	-0.67	-0.07	0.3	-0.52	0.6	-0.79		-0.9	-0.78	-0.28	-0.14	-0.33	0.58	0.32
Capital Surpluse	0.66	0.7	-0.7	-0.9	0.45	-0.02	0.7	-0.14	-0.45	0.6	-0.53	0.88	-0.9		0.91	0.36	0.24	0.45	-0.7	-0.23
Property Plant Equipment	0.72	0.73	-0.68	-0.9	0.57	0.05	0.73	-0.27	-0.43	0.52	-0.47	0.94	-0.78	0.91		0.4	0.2	0.42	-0.74	-0.45
Net Invested Capital	0.72	0.77	-0.79	-0.3	0.0	-0.15	0.74	-0.45	-0.72	0.38	-0.17	0.36	-0.28	0.36	0.4		0.96	0.97	-0.58	-0.1
Net Working Capital	0.56	0.61	-0.67	-0.11	-0.22	-0.19	0.58	-0.36	-0.7	0.35	-0.08	0.14	-0.14	0.24	0.2	0.96		0.96	-0.41	0.15
Short Term Investments	0.66	0.72	-0.77	-0.32	-0.1	-0.18	0.68	-0.38	-0.77	0.47	-0.2	0.34	-0.33	0.45	0.42	0.97	0.96		-0.55	0.07
Capital Stock	-0.83	-0.85	0.79	0.85	-0.64	-0.15	-0.85	0.73	0.68	-0.21	0.34	-0.87	0.58	-0.7	-0.74	-0.58	-0.41	-0.55		0.46
Short Long Term Debt	-0.52	-0.49	0.33	0.45	-0.79	-0.15	-0.52	0.3	-0.12	-0.01	0.18	-0.59	0.32	-0.23	-0.45	-0.1	0.15	0.07	0.46

Click cells to compare fundamentals

Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.

Competition

Predict Lexaria Bioscience

Lexaria Common Stock Shares Outstanding

Common Stock Shares Outstanding

14.95 Million

At this time, Lexaria Bioscience's Common Stock Shares Outstanding is fairly stable compared to the past year.

According to the company disclosure, Lexaria Bioscience Corp has an Earnings Per Share of 0.0 times. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

Lexaria Bioscience Current Valuation Drivers

We derive many important indicators used in calculating different scores of Lexaria Bioscience from analyzing Lexaria Bioscience's financial statements. These drivers represent accounts that assess Lexaria Bioscience's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Lexaria Bioscience's important valuation drivers and their relationship over time.

	2020	2021	2022	2023	2024	2025 (projected)
Market Cap	27.3M	17.4M	6.9M	48.4M	115.2M	120.9M
Enterprise Value	16.5M	11.7M	5.8M	42.1M	116.4M	122.2M

Lexaria Fundamentals

	Return On Equity	-0.71
	Return On Asset	-0.38
	Operating Margin	(20.75) %
	Number Of Shares Shorted	6.41 K
	Revenue	464.28 K
	Gross Profit	406.2 K
	EBITDA	(5.68 M)
	Net Income	(5.81 M)
	Cash And Equivalents	1.31 M
	Cash Per Share	0.44 X
	Total Debt	137.37 K
	Debt To Equity	0.06 %
	Current Ratio	8.52 X
	Book Value Per Share	0.64 X
	Cash Flow From Operations	(4.96 M)
	Beta	1.06
	Market Capitalization	33.79 M
	Total Asset	8.87 M
	Retained Earnings	(51.56 M)
	Working Capital	1.93 M
	Net Asset	8.87 M

About Lexaria Bioscience Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Lexaria Bioscience Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lexaria Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lexaria Bioscience Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

Additional Tools for Lexaria Stock Analysis

When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC